Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Argus Health
Baxter
AstraZeneca
Teva
Fuji
McKesson
Mallinckrodt
Boehringer Ingelheim

Generated: September 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,686,411

« Back to Dashboard

Which drugs does patent 5,686,411 protect, and when does it expire?

Patent 5,686,411 protects SYMLIN and is included in one NDA.

This patent has thirty-two patent family members in sixteen countries.

Summary for Patent: 5,686,411
Title: Amylin agonist peptides and uses therefor
Abstract:Agonist analogues of amylin and related pharmaceutical compositions, and methods of treatment of diabetes and other insulin-requiring states, as well as methods of treatment of hypoglycemia, are provided.
Inventor(s): Gaeta; Laura S. L. (Foster City, CA), Jones; Howard (Poway, CA), Albrecht; Elisabeth (San Diego, CA)
Assignee: Amylin Pharmaceuticals, Inc. (San Diego, CA)
Application Number:08/447,849
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

Drugs Protected by US Patent 5,686,411

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca Ab SYMLIN pramlintide acetate INJECTABLE;SUBCUTANEOUS 021332-002 Sep 25, 2007 RX Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN ➤ Sign Up
Astrazeneca Ab SYMLIN pramlintide acetate INJECTABLE;SUBCUTANEOUS 021332-003 Sep 25, 2007 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN ➤ Sign Up
Astrazeneca Ab SYMLIN pramlintide acetate INJECTABLE;SUBCUTANEOUS 021332-001 Mar 16, 2005 DISCN No No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 5,686,411

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 205854 ➤ Sign Up
Australia 1245697 ➤ Sign Up
Australia 3075392 ➤ Sign Up
Australia 673147 ➤ Sign Up
Australia 714439 ➤ Sign Up
Canada 2100745 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Healthtrust
QuintilesIMS
AstraZeneca
US Department of Justice
Chinese Patent Office
Cantor Fitzgerald
Express Scripts
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.